Stocks in play: Sernova Corp.

Announced today that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the Company through the development of its pioneering Cell Pouch System™ and ensuing growth, Dr. Philip Toleikis, President and Chief Executive Officer will be appointed Sernova’s Chief Technology Officer (CTO). To achieve a seamless transition and continue progress on all Company activities, Dr. Toleikis will remain in the CEO role during the search period and continue to work closely with Executive Chair, Frank Holler. Mr. Holler will, in particular, take a leadership role and work closely with Dr. Toleikis in advancing Sernova’s business development and corporate finance activities during the search period. Sernova Corp. shares T.SVA are trading unchanged at $0.91.

Read:

• Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

• Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

• Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

• New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates

• Highly Sought After Natural Ingredients Appearing in More Plant-Based Products Across North America